facebook
eISSN: 2084-9893
ISSN: 0033-2526
Dermatology Review/Przegląd Dermatologiczny
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
2/2010
vol. 97
 
Share:
Share:
abstract:
Original paper

Failures of non-melanoma skin cancer therapy

Adam Włodarkiewicz
,
Michał Sobjanek
,
Igor Michajłowski
,
Anita Warzecha

Przegl Dermatol 2010, 97, 69–73
Online publish date: 2010/04/30
View full text Get citation
 
Introduction. During three months of 2009, 177 patients with non-melanoma skin cancers (NMSCs) referred to the department for consultation and planning of therapeutic procedures were examined. The majority of them (131) presented recurrent or noncured neoplasms. Tumours were located in the head and neck region and 56.6% of them in areas of high risk of recurrence and metastases.
Objective. To analyse the reasons for failure of the first treatment of non-melanoma skin cancers.
Results. Treatment failures were observed most frequently in cases of basal cell carcinoma. In this group over 66% of tumours presented one or more clinical high-risk factors and 11% histopathological features of aggressiveness. Over 29% of all lesions were treated without histopathological verification of clinical diagnosis. Among patients with recurrence or uncured cancers 75% were treated by cryodestruction of the lesions. Surgical excision was performed in a small minority of cases and 52% of those tumours were not radically resected.
Conclusions. Failures of the first treatment of cutaneous cancers causes significant difficulties in following surgical management, including reconstruction dilemmas as well as the necessity of complementary radiotherapy, especially in cases in which oncological “clearness” is difficult to achieve.
keywords:

non-melanoma skin cancer, treatment failures



Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.